Ayman El-kadi

Biography

Dr. El-Kadi is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (Edmonton, Alberta, Canada) since 2001. At University of Alberta he moved through the ranks from Assistant to Full Professor. He was the Chair of Pharmaceutical Sciences Division (2005-2008), Director of Graduate Studies (2008-2009), and the Associate Dean for Research and Graduate Studies (2009-2013). Dr. El-Kadi received his BSc in Pharmacy and MSc in Pharmacology from Tripoli and Benghazi University (Libya) in 1990 and 1994, respectively. In 1999 he received his PhD in Pharmacology from University of Montreal (Montreal, Quebec, Canada). Thereafter, he did postdoctoral training in Molecular Toxicology at the University of Western Ontario (London, Ontario, Canada). Dr. El-Kadi’s research interests are in the areas of Pharmacology and Molecular and Environmental Toxicology. His research resulted in over 130 peer-reviewed papers in prestigious journals and similar number of abstracts and presentations. His research is supported by the Natural Sciences and Engineering Research Council (NSERC), Canadian Institute of Health Research (CIHR), Heart and Stroke Foundation of Canada, Canadian Foundation for Innovation (CFI) and several Biotech companies. He has supervised significant number of undergraduate, MSc, PhD students and postdoctoral fellows. He has served as editor, associate editor and member of the editorial board for a number of journals in the pharmaceutical sciences. Dr. El-Kadi is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (Edmonton, Alberta, Canada) since 2001. At University of Alberta he moved through the ranks from Assistant to Full Professor. He was the Chair of Pharmaceutical Sciences Division (2005-2008), Director of Graduate Studies (2008-2009), and the Associate Dean for Research and Graduate Studies (2009-2013). Dr. El-Kadi received his BSc in Pharmacy and MSc in Pharmacology from Tripoli and Benghazi University (Libya) in 1990 and 1994, respectively. In 1999 he received his PhD in Pharmacology from University of Montreal (Montreal, Quebec, Canada). Thereafter, he did postdoctoral training in Molecular Toxicology at the University of Western Ontario (London, Ontario, Canada). Dr. El-Kadi’s research interests are in the areas of Pharmacology and Molecular and Environmental Toxicology. His research resulted in over 130 peer-reviewed papers in prestigious journals and similar number of abstracts and presentations. His research is supported by the Natural Sciences and Engineering Research Council (NSERC), Canadian Institute of Health Research (CIHR), Heart and Stroke Foundation of Canada, Canadian Foundation for Innovation (CFI) and several Biotech companies. He has supervised significant number of undergraduate, MSc, PhD students and postdoctoral fellows. He has served as editor, associate editor and member of the editorial board for a number of journals in the pharmaceutical sciences.

Research Interest

1. Understanding (i) the potential interaction between heavy metals and aryl hydrocarbon receptor (AhR) ligands which are common in the environment on the regulation of AhR-regulated genes, and (ii) investigate the effects of AhR ligand/metal mixtures on AhR ligands-mediated mutagenicity and carcinogenicity. These studies will a) increase our knowledge about the effect of heavy metals on the AhR-regulated genes, and b) provide the information that will help to design strategies to improve treatment of AhR ligands mediated mutagenicity and carcinogenicity. 2. Understanding the role of cytochrome P450 (CYP) enzymes in the pathogenesis of cardiac hypertrophy. Understanding the pathogenesis of cardiac hypertrophy may provide important clues for the development of rational therapies for the prevention and treatment of heart failure. The development of these rational therapies will decrease morbidity and mortality and hence diminish health care costs. 3. To identify an aryl hydrocarbon receptor antagonist from natural source that may serve as anticancer drug.